IP Verse

Use Of An Antibody Directed Against A Membrane Protein - EP2651978

The patent EP2651978 was granted to Laboratoire Franais DU Fractionnement ET DES Biotechnologies on Jan 12, 2022. The application was originally filed on Dec 12, 2011 under application number EP11811089A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2651978

LABORATOIRE FRANAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Application Number
EP11811089A
Filing Date
Dec 12, 2011
Status
Patent Maintained As Amended
Dec 10, 2021
Grant Date
Jan 12, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

MILTENYI BIOTECFeb 9, 2018HEIDEADMISSIBLE

Patent Citations (18) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP1301539
DESCRIPTIONEP1783141
DESCRIPTIONUS2010189641
DESCRIPTIONWO0136487
DESCRIPTIONWO2006037247
INTERNATIONAL-SEARCH-REPORTUS2010189641
INTERNATIONAL-SEARCH-REPORTWO0136487
INTERNATIONAL-SEARCH-REPORTWO0138496
OPPOSITIONEP1301539
OPPOSITIONFR1060428
OPPOSITIONUS2018066060
OPPOSITIONUS2018086834
OPPOSITIONWO0138496
OPPOSITIONWO2004024768
OPPOSITIONWO2008137382
OPPOSITIONWO2012080642
OPPOSITIONWO2014093396
OTHEREP1783141

Non-Patent Literature (NPL) Citations (64) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BLOMBERG ET AL., ARTHRITIS AND RHEUMATISM, (2003), vol. 48, no. 9, pages 2524 - 2532-
DESCRIPTION- CHAPEROT L ET AL., BLOOD, (20010515), vol. 97, no. 10, pages 3210 - 3217-
DESCRIPTION- GONZALES-STAWINSKI, CLIN IMMUNOL, (2001), vol. 98, page 175-
DESCRIPTION- HERLING M; JONES D., AM J CLIN PATHOL., (200705), vol. 127, no. 5, pages 687 - 700-
DESCRIPTION- HOUGLUM, JE, (1893), vol. 2, page 20-
DESCRIPTION- LEVESQUE MC, ARTHRITIS RHEUM, (1999), vol. 42, page 569-
DESCRIPTION- LOONEY, ANN RHEUM DIS, (2002), vol. 61, page 863-
DESCRIPTION- NESTLE ET AL., J. EXP. MED, (2005), vol. 202, no. L, pages 135 - 143-
DESCRIPTION- NG AP ET AL., HAEMATOLOGICA, (2006), vol. 91, no. 1, pages 143 - 14-
DESCRIPTION- PAPOT, REV MED INTERNE, (2002), vol. 23, no. 4-
EXAMINATION- FEUILLARD JEAN ET AL, "Clinical and biologic features of CD4(+)CD56(+) malignancies.", BLOOD 1 MAR 2002, (20020301), vol. 99, no. 5, ISSN 0006-4971, pages 1556 - 1563-
EXAMINATION- FRANKEL ARTHUR E ET AL, "Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.", BLOOD 17 JUL 2014, (20140717), vol. 124, no. 3, ISSN 1528-0020, pages 385 - 392-
EXAMINATION- GARNACHE-OTTOU, "Une nouvelle entité: les leucémies CD4+ CD56+ dérivées des cellules dendritiques plasmocytoïdes", SCTRA BIOLOGIE, (20050901), vol. 147, pages 49 - 58-
EXAMINATION- ZÖLLER M ET AL, "IgG- and IgM-induced cellular cytotoxicity.", SCANDINAVIAN JOURNAL OF IMMUNOLOGY NOV 1982, (198211), vol. 16, no. 5, ISSN 0300-9475, pages 379 - 388-
EXAMINATION- N. KARAGIANNIS ET AL, "Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells", EUROPEAN JOURNAL OF IMMUNOLOGY, (20030401), vol. 33, no. 4, doi:10.1002/eji.200323185, ISSN 0014-2980, pages 1030 - 1040, XP055038303
EXAMINATION- CHAPEROT L ET AL, "Identification of a leukemic counterpart of the plasmacytoid dendritic cells", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, (20010515), vol. 97, no. 10, doi:10.1182/BLOOD.V97.10.3210, ISSN 0006-4971, pages 3210 - 3217, XP002243855
INTERNATIONAL-SEARCH-REPORT- GARNACHE-OTTOU FRANCINE ET AL, "Identification of BDCA-2 and high levels of CD123 expression as useful markers for the diagnosis of plasmacytoid dendritic cell leukemia", BLOOD, vol. 106, no. Abst. 3269, (200511), ASH Annual Meeting Abstracts, URL: http://abstracts.hematologylibrary.org/cgi/content/abstract/106/11/3269?maxtoshow=&hits=50&RESULTFORMAT=&searchid=1&FIRSTINDEX=150&displaysectionid=Poster+Sessions&fdate=1/1/2005&tdate=12/31/2005&resourcetype=HWCIT, (20120307), XP002670970 [Y] 1-10 * abstract *-
INTERNATIONAL-SEARCH-REPORT- LONARDI S ET AL, "A monoclonal antibody anti-BDCA2 (CD303) highly specific for plasmacytoid dendritic cell neoplasms on paraffin sections", VIRCHOWS ARCHIV, & 22ND EUROPEAN CONGRESS OF PATHOLOGY; FLORENCE, ITALY; SEPTEMBER 04 09, 2009, (200908), vol. 455, no. Suppl. 1, ISSN 0945-6317, pages 254 - 255, XP002644181 [Y] 1-10 * abstract *-
INTERNATIONAL-SEARCH-REPORT- JAYE DAVID L ET AL, "Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+CD56+hematodermic neoplasms", MODERN PATHOLOGY, NATURE PUBLISHING GROUP, US, (20060901), vol. 19, no. 12, doi:10.1038/MODPATHOL.3800679, ISSN 0893-3952, pages 1555 - 1562, XP002481366 [Y] 1-10 * paragraph [discussion] *
OPPOSITION- Bosley, A, "Anticorps monoclonal anti-CD20 dans les maladies hématologiques et les affections auto-immunes", Réanimation, (20070000), vol. 15, pages 270 - 277-
OPPOSITION- Cao et al, "Plamacytoid dendritic cell-specific receptor ILT7-FceRIy inhibits Toll-like receptor-induced interferon production", The Journal of Experimental Medicine, (20060612), vol. 203, no. 6, pages 1399 - 1405-
OPPOSITION- CHAPEROT et al., "Leukemic plasmacytoid dendritic cells share phenotypic and functional features with their normal counterparts", Eur. J. Immunol., (20040201), vol. 34, no. 2, pages 418 - 426-
OPPOSITION- CHARLES et al., "Plasmacytoid dendritic cells and dermatological disorders: focus on their role in autoimmunity and cancer", Eur J Dermatol, (20100000), vol. 20, no. 1, pages 1 - 8-
OPPOSITION- CHARLES et al., "Plasmacytoid dendritic cells and dermatological disorders: focus on their role in autoimmunity and cancer", Eur J Dermatol, (20100000), vol. 20, no. 1, pages 1 - 8, XP055463394-
OPPOSITION- De Romeuf et al, "Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIII/CD16.", British Journal of Haematology, (20080000), vol. 140, pages 635 - 643-
OPPOSITION- DZIONEK et al., "BDCA-2, a Novel Plasmacytoid Dendritic Cell -specific Type II C-type Lectin, Mediates Antigen Capture and Is a Potent Inhibitor of Interferon alpha/beta Induction", JEM, (20011217), vol. 194, no. 12, pages 1823 - 1834-
OPPOSITION- DZIONEK et al., "BDCA-2, BDCA-3, and BDCA-4: Three Markers for Distinct Subsets of Dendritic Cells in Human Peripheral Blood", The Journal of Immunology, (20000000), vol. 165, pages 6037 - 6046-
OPPOSITION- DZIONEK et al., "BDCA-2, BDCA-3, and BDCA-4: Three Markers for Distinct Subsets of Dendritic Cells in Human Peripheral Blood", The Journal of Immunology, (20000000), vol. 165, pages 6037 - 6046, XP000986292-
OPPOSITION- DZIONEK et al., "Plasmacytoid Dendritic Cells: From Specific Surface Markers to Specific Cellular Functions", Human Immunology, (20020000), vol. 63, pages 1133 - 1148-
OPPOSITION- FACHETTI et al., "Blastic plasmacytoid dendritic cell neoplasm", Hematology Meeting Reports, (20090000), vol. 3, no. 3, pages 1 - 3-
OPPOSITION- FACHETTI et al., "Blastic plasmacytoid dendritic cell neoplasm", Hematology Meeting Reports, (20090000), vol. 3, no. 3, pages 1 - 3, XP055463388-
OPPOSITION- GARNACHE-OTTOU et al., "Extended diagnostic criteria for plasmacytoide dendritic cell leukaemia", British Journal of Hematology, vol. 145, pages 624 - 636-
OPPOSITION- GARNACHE-OTTOU et al., "Identification of BDCA-2 and High Levels of CD 123 Expression as Useful Markers for the Diagnosis of Plasmacytoid Dendritic Cell Leukemia", Blood, (20050000), vol. 106, page 3269, XP002670970-
OPPOSITION- GARNACHE-OTTOU et al., "Une nouvelle entite: les leucemies CD 4+ CD 56+ ou leucemies derivees des cellules dendritiques plasmocytoides", Spectra Biologie, (20050900), pages 49 - 58, XP055463373-
OPPOSITION- Hansel et al, "The safety and side effects of monoclonal antibodies", Nature Reviews Drug Discobery, (20100000), vol. 9, pages 325 - 338-
OPPOSITION- Karagiannis et al, "Activity of human monocytes in IgE antibodydependent surveillance and killing of ovarian tumor cells", Eur. J. Immunol., (20030000), vol. 33, pages 1030 - 1040-
OPPOSITION- Kovtun et al, "A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells", Blood Advances, (20180000), vol. 2, pages 848 - 858-
OPPOSITION- Legrand et al, "Functional CD47/signal regulatory protein alpha (SIRPalpha) interaction is required for optimal human T- and natural killer-(NK) cell homeostasis in vivo", PNAS, (20110000), vol. 108, no. 32, pages 13224 - 13229-
OPPOSITION- LONARDI et al., "A monoclocal antibody anti-BDCA2 ( CD 303) highly specific for plasmacytoid dendritic cell neoplasm on paraffin sections", Virchows Archiv, (20090800), vol. 455, no. 1, pages 254 - 255, XP002644181-
OPPOSITION- Ludwig et al, "Monoclonal antibody therapeutics and apoptosis", Oncogene, (20030000), vol. 22, pages 9097 - 9106-
OPPOSITION- Maeda et al, "A novel plasmacytoid dendritic cell line, CAL-1, established from a patient with blastic natural killer cell lymphoma", Int J Hematol., (20050200), vol. 81, no. 2, pages 148 - 154-
OPPOSITION- MITCHEL L et al., "Depletion of B Cells In Vivo by a Chimeric Mouse Human Monoclonal Antibody to CD 20", Blood, (19940115), vol. 83, no. 2, pages 435 - 445-
OPPOSITION- Natsume et al, "Engineered Antibodies of IgGl/lgG3 Mixed Isotope with Enhanced Cytotoxic Activities", Cancer Res., (20080515), vol. 68, no. 10-
OPPOSITION- NESTLE et al., "Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production", JEM, (20050704), vol. 202, no. 1, pages 135 - 143-
OPPOSITION- PETRELLA et al., "Tumoral aspects of plasmacytoid dendritic cells: What do we know in 2009?", Autoimmunity, (20100500), vol. 43, no. 3, pages 210 - 214-
OPPOSITION- PETRELLA et al., "Tumoral aspects of plasmacytoid dendritic cells: What do we know in 2009?", Autoimmunity, (20100500), vol. 43, no. 3, pages 210 - 214, XP055463392-
OPPOSITION- Testa et al, "CD123 is a membrane biomarker and a therapeutic target in hematologic malignancies", Biomarker Research, (20140000), vol. 2, no. 4-
OPPOSITION- WEINER et al., "Rituximab: mechanism of action", Semin Hematol, (20100400), vol. 47, no. 2, pages 115 - 123-
OPPOSITION- WINKLER et al., "Cytokine-Release Syndrome in Patients With B- Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti- CD 20 Monoclonal Antibody (Rituximab, IDEC-C2B8", Blood, (19990000), vol. 94, no. 7, pages 2217 - 2224-
OPPOSITION- WINKLER et al., "Cytokine-Release Syndrome in Patients With B- Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti- CD 20 Monoclonal Antibody (Rituximab, IDEC-C2B8", Blood, (19990000), vol. 94, no. 7, pages 2217 - 2224, XP001022211-
OPPOSITION- Zola et al, "CD molecules 2005: human cell differentation molecules", Blood, (20051101), vol. 106, no. 9-
OPPOSITION- Zöller et al, "IgG- and IgM-induced cytotoxicity", Scand. J. Immunol., (19820000), vol. 16, pages 379 - 388-
OPPOSITION- CHAPEROT et al., "Leukemic plasmacytoid dendritic cells share phenotypic and functional features with their normal counterparts", Eur. J. Immunol., (20040201), vol. 34, no. 2, pages 418 - 426, XP002505517
OPPOSITION- DZIONEK et al., "Plasmacytoid Dendritic Cells: From Specific Surface Markers to Specific Cellular Functions", Human Immunology, (20020000), vol. 63, pages 1133 - 1148, XP002243856
OPPOSITION- JAYE et al., "Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD 4+ CD 56+ hematodermic neoplasms", Modern Pathology, (20060000), vol. 19, pages 1555 - 1562, XP002481366
OPPOSITION- WEINER et al., "Rituximab: mechanism of action", Semin Hematol, (20100400), vol. 47, no. 2, pages 115 - 123, XP055463384
OPPOSITION- DZIONEK et al., "BDCA-2, a Novel Plasmacytoid Dendritic Cell -specific Type II C-type Lectin, Mediates Antigen Capture and Is a Potent Inhibitor of Interferon alpha/beta Induction", JEM, (20011217), vol. 194, no. 12, pages 1823 - 1834, XP002277387
OPPOSITION- NESTLE et al., "Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production", JEM, (20050704), vol. 202, no. 1, pages 135 - 143, XP002364226
OPPOSITION- GARNACHE-OTTOU et al., "Extended diagnostic criteria for plasmacytoide dendritic cell leukaemia", British Journal of Hematology, vol. 145, pages 624 - 636, XP055366737
OPPOSITION- MITCHEL L et al., "Depletion of B Cells In Vivo by a Chimeric Mouse Human Monoclonal Antibody to CD 20", Blood, (19940115), vol. 83, no. 2, pages 435 - 445, XP002112549
OTHER- FACCHETTI et al., "Blastic plasmacytoid dendritic ceH neoplasm", Hematology Meeting Reports, (20090000), vol. 3, no. 3, pages 1 - 3, XP055366739-
OTHER- CHAPEROT et al., "Leukemic plasmacytoid dendritic cells share phenotypic and functional features with their normal counterparts", European Journal of Immunology, (20040200), vol. 34, no. 2, pages 418 - 426, XP002505517
OTHER- GARNACHE-OTTOU et al., "Extended diagnostic criteria for plasmacytoid dendritic cellleukaemia", British Journal of Haematology, (20090600), vol. 145, no. 5, pages 624 - 636, XP055366737
OTHER- PILICHOWSKA M.E. et al., "CD4+/CD56+ Hematodermic Neoplasm (Blastic NaturalKiller Cell Lymphoma)", Am J Clin Pathol, (20070900), vol. 128, no. 3, pages 445 - 453, XP055366744

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents